SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma

Official title

A Randomized, Open-Label, Controlled, Multicenter Phase 2 Trial of SYS6002 Versus PADCEV in Patients With Advanced Urothelial Carcinoma

Overview

This study is a randomized, open-label, controlled, multicenter phase II clinical trial, which aims to evaluate the safety and efficacy of SYS6002 versus enfortumab vedotin in the treatment of participants with advanced urothelial carcinoma. This study has not yet been submitted for ethical review. The current registration is a pre-registration. Recruitment will be initiated only after formal approval is obtained from the relevant Ethics Committee or Institutional Review Board.

Interventions

• Drug SYS6002
  SYS6002 by intravenous (IV)
• Drug enfortumab vedotin
  1.25 mg/kg by IV on Day 1、8、15, every 28 days.

Primary outcome measures

• Occurrence and frequency of Adverse Event (AE) [Time frame: Up to approximately 2 years]

Secondary outcome measures (8)

• Incidence of treatment-related peripheral neuropathy and≥1-grade worsening in treatment-related peripheral neuropathy from baseline [Time frame: Up to 2 years]
• Incidence of treatment-related hyperglycemia [Time frame: Up to 2 years]
• Incidence of treatment-related cutaneous adverse reactions [Time frame: Up to 2 years]
• Objective Response Rate (ORR) [Time frame: Up to 2 years]
• Duration of Response (DOR) [Time frame: Up to 2 years]
• Disease Control Rate (DCR) [Time frame: :Up to 2 years]
• Progression Free Survival (PFS) [Time frame: Up to 2 years]
• Overall Survival [Time frame: Up to 2 years]

Eligibility criteria

Inclusion criteria

• 1\. Patients aged 18-80 years (inclusive);
• 2\. Pathologically confirmed patients with advanced urothelial carcinoma who have received a platinum-based chemotherapy with anti-PD-(L)1 agent. For those who received these therapies in the adjuvant or neoadjuvant setting, disease progression must have occurred during treatment or within 12 months of treatment completion;
• 3 An archival tumor tissue sample or a fresh tissue sample should be provided;
• 4 Subjects must have measurable disease according to RECIST (version 1.1);
• 5 Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
• 6 Life expectancy of ≥ 3 months;
• 7 Major organ function must meet the relevant laboratory test standards for hematology, renal function, liver function, and coagulation within 7 days prior to treatment;
• 8Sexually active fertile subjects must agree to use methods of contraception during the study and at least 7 months after termination of study therapy and have a negative urine or serum pregnancy test within 7 days prior to randomization;
• 9.Willing to participate in the study, understand the study procedures, and sign a written informed consent form.

Exclusion criteria

• 1.Active central nervous system metastases or leptomeningeal metastasis;
• 2.Adverse events from prior anti-tumor therapy not recovered to ≤ Grade 1 (unless the investigator deems there is no safety risk)；
• 3.Any serious and/or uncontrolled concurrent illness that may interfere with patient's participation in the study:

• Participants with a history of severe cardiovascular disease within 6 months prior to randomization, including but not limited to:

Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmia and third-degree atrioventricular block requiring clinical intervention; corrected QT interval > 480 ms by Fridericia method (Fridericia formula: QTcF = QT/RR\^0.33, RR = 60/heart rate); With history of myocardial infarction, unstable angina pectoris, angioplasty and coronary artery bypass surgery; New York Heart Association (NYHA) classification Grade III and above heart failure, and left ventricular ejection fraction (LVEF) < 50% in the tests and examinations during the screening period; cerebrovascular accidents; pulmonary embolisms;

• Other clinically significant diseases:

HbA1c > 8%; Participants with active keratitis and corneal ulcer, or fundus lesions with a risk of blindness; Grade ≥2 neuropathy prior to randomization; Severe infection within 4 weeks prior to randomization; active infection requiring systemic antibiotics, antiviral, or antifungal therapy within 2 weeks prior to randomization; Active HBV or HCV infection; History of immunodeficiency (HIV-positive, acquired or congenital immunodeficiency, etc.), or organ transplantation; History of another malignancy within 3 years prior to randomization; History of interstitial lung disease (ILD) / non-infectious pneumonia, or current ILD/non-infectious pneumonia, or imaging findings at screening that cannot rule out these conditions, except for those who are determined to be risk-free after discussion between the investigator and the sponsor; Pleural effusion, ascites or pericardial effusion with symptoms or requiring puncture or drainage within 2 weeks prior to randomization;

• 4.Use of other unmarketed clinical investigational drugs or treatments, chemotherapy, radiotherapy targeted therapy within 4 weeks prior to randomization; use of traditional Chinese medicine with anticancer indication, oral fluoropyrimidine drugs, small molecule targeted drug within 2 weeks prior to randomization; use of palliative radiation or local therapy within 2 weeks prior to randomization;with major surgery within 4 weeks prior to randomization;
• 5.Allergy to any component of SYS6002, or humanized monoclonal antibodies; investigator-determined ineligibility for enfortumab vedotin therapy.
• 6\. Other conditions deemed by the investigator as unsuitable for participation in this clinical trial.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07374549 · SYS6002-00X

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗